RESUMO
In December 2019, an epidemic of cases with unexplained lower respiratory infections detected in Wuhan, China was first reported to the WHO China Office. The respiratory picture presents in various ways, from asymptomatic or paucisymptomatic forms, to clinical conditions characterized by respiratory failure that require mechanical ventilation and support in the ICU, with multi-organ and systemic manifestations in terms of sepsis, septic shock and multiple organ dysfunction syndromes. The etiological agent was identified as a virus belonging to the coronavirus family (CoV) with a high contagion capacity that determined its rapid spread, triggering a pandemic with high morbidity and mortality. This review attempts to address the basics of this disease.
Assuntos
Humanos , Pneumonia Viral/fisiopatologia , COVID-19/etiologia , COVID-19/transmissão , Asma , Tórax/diagnóstico por imagem , Tomografia Computadorizada por Raios X , Diagnóstico Clínico , Sepse , Técnicas e Procedimentos Diagnósticos , Doença Pulmonar Obstrutiva Crônica , Diagnóstico Diferencial , SARS-CoV-2 , COVID-19/diagnóstico , COVID-19/fisiopatologia , COVID-19/prevenção & controle , COVID-19/terapia , COVID-19/epidemiologiaRESUMO
There are increasingly more data on the prevalence and distribution of Chronic Obstructive Pulmonary Disease (COPD) from around the world. COPD is predicted to be the third most frequent cause of death in the world by 2020. COPD is mainly caused by chronic tobacco smoking, which induces important changes in both the airways and lung parenchyma. COPD is a progressive, disabling condition that ultimately ends in respiratory failure and death. Is a multicomponent disease, there is evidence that systemic inflammation and extrapulmonary effects are also common in COPD, although the association between systemic inflammation and systemic manifestations of COPD is still not entirely clear. COPD has been associated with a nihilistic attitude. On the basis of current evidence, this nihilistic attitude is totally unjustified. The disease must be viewed through the lens of a new paradigm: COPD is not only preventable but also treatable. The past decade has witnessed great progress in COPD research. New drugs have been developed and tested and a growing base of scientific evidence now documents the efficacy of various therapies for symptoms and exacerbations. It is clear that many patients with COPD can benefit from aggressive management, with a decrease in the frequency of hospitalizations and improvements in symptoms and quality of life. In addition, basic and clinical scientists have now identified cells, mechanisms, and molecules that appear to play key roles in disease pathogenesis. Additional novel treatments are on the horizon and the advent of newer and more effective therapies will lead to a decline in the contribution of this disease to poor world health. The good news about COPD is to increase awareness of the disease. COPD is now viewed under a new paradigm as preventable and treatable.
Assuntos
Humanos , História do Século XXI , Doença Pulmonar Obstrutiva Crônica/diagnóstico , Doença Pulmonar Obstrutiva Crônica/mortalidade , Testes de Função Respiratória , Tabagismo , Bronquite Crônica , Doença Pulmonar Obstrutiva Crônica/história , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Doença Pulmonar Obstrutiva Crônica/reabilitação , Doença Pulmonar Obstrutiva Crônica/terapia , Enfisema , LinfonodosRESUMO
BACKGROUND: Exposure to noxious gases and particles contained in both tobacco smoking (TS) and biomass smoke (BS) are well recognized environmental risk factors for chronic obstructive pulmonary disease (COPD). COPD is characterized by an abnormal inflammatory response, both in the pulmonary and systemic compartments. The differential effects of TS, BS or their combined exposure have not been well characterized yet. This study sought to compare the lung function characteristics and systemic inflammatory response in COPD patients exposed to TS, BS or their combination. METHODS: Sociodemographic, clinical and lung functional parameters were compared across 49 COPD patients with a history of smoking and no BS exposure (TS COPD), 31 never-smoker COPD patients with BS exposure (BS COPD), 46 COPD patients with a combined exposure (TS + BS COPD) and 52 healthy controls (HC) who have never been exposed neither to TS or BS. Blood cell counts, C-reactive protein (CRP), fibrinogen and immunoglobulin E (IgE) levels were quantified in all four groups. RESULTS: TS + BS COPD patients exhibited significantly lower oxygen saturation than the rest of groups (p < 0.01). Spirometry and diffusing capacity were significantly higher in BS than in TS or TS + BS patients. CRP levels were significantly higher in TS COPD patients than in BS COPD group (p < 0.05), whereas fibrinogen was raised in COPD patients with a history of smoking (TS and TS + BS) when compared to control subjects (p < 0.01). Finally, COPD patients with BS exposure (BS and BS + TS groups) showed higher IgE levels than TS and HC (p < 0.05). CONCLUSIONS: There are significant physiological and inflammatory differences between COPD patients with TS, BS and TS + BS exposures. The latter had worse blood oxygenation, whereas the raised levels of IgE in BS exposed patients suggests a differential Th2 systemic inflammatory pattern triggered by this pollutant.
Assuntos
Biomassa , Exposição Ambiental/efeitos adversos , Doença Pulmonar Obstrutiva Crônica/sangue , Doença Pulmonar Obstrutiva Crônica/diagnóstico , Fumaça/efeitos adversos , Fumar Tabaco/efeitos adversos , Idoso , Idoso de 80 Anos ou mais , Feminino , Volume Expiratório Forçado/fisiologia , Humanos , Mediadores da Inflamação/sangue , Masculino , Pessoa de Meia-Idade , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , Espirometria/métodos , Espirometria/tendências , Fumar Tabaco/tendênciasRESUMO
El objetivo de esta comunicación fue evaluar el perfil epidemiológico de los pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) de la Región del Maule. Para ello, se contó con 127 pacientes EPOC clínicamente estables derivados por parte del neumólogo o que fueron atendidos en el centro de diagnóstico terapéutico del Hospital Regional de Talca durante el año 2016. Los pacientes fueron sometidos a una serie de pruebas de función pulmonar y debieron contestar un cuestionario para conocer antecedentes clínicos y epidemiológicos. Tras el estudio, fueron clasificados de acuerdo al criterio GOLD que integra medidas de síntomas, disnea, espirometría y riesgo de exacerbaciones. El 56% de los pacientes fueron varones y el promedio de edad en ambos sexos fue de 71,4 años (IC 95% 67,89-71,28). Un 27% tuvieron un nivel de escolarización ≤ 4 años. El 25% fueron clasificados como GOLD A, el 33% B, el 9% C y el 33% D. El 61% de los pacientes presentaron una exposición significativa simultánea a humo de cigarrillo y humo de biomasa. Los pacientes EPOC de la Región del Maule son fundamentalmente varones, adultos mayores y, frecuentemente, con bajo nivel de escolaridad. Los principales factores de riesgo para el desarrollo de la enfermedad en esta cohorte fueron la exposición simultánea a humo de tabaco y de combustibles de biomasa. La mayoría de los pacientes se encuentran en los estadios más leves de la enfermedad. Nuestros hallazgos identificaron las principales áreas que deben ser intervenidas para mejorar el manejo de la EPOC en la Región del Maule.
This study aimed to assess the epidemiological profile of subjects from the Maule Region (Chile) suffering from Chronic Obstructive Pulmonary Disease (COPD). We recruited 127 stable-COPD patients who were attended by a pulmonologist or treated at Hospital Regional de Talca during 2016. All patients underwent lung functional tests and answered a standardized questionnaire to obtain clinical and epidemiological data. Patients were classified according to the GOLD combined COPD assessment criteria, which included symptomatic assessment with the patient's spirometric classification and risk of exacerbations. GOLD A, B, C and D categories consisted of 25%, 33%, 9% and 33% of patients respectively. The mean age was 71.4 years (CI 95% 64.7-73.7) and 56% of the patients were male. A 27% of subjects completed 4 or less years of schooling. 61% of patients showed a significant combined exposure to both cigarette and biomass smoke. COPD patients from the Maule Region are mostly elderly male, often showing a low educational level. The main COPD risk factor in this cohort was the simultaneous exposure to cigarette and biomass smoke. Most patients are in the milder stages of COPD. Our findings identified the main areas that can be intervened to improve COPD management in the Maule Region.
Assuntos
Humanos , Masculino , Feminino , Idoso , Idoso de 80 Anos ou mais , Doença Pulmonar Obstrutiva Crônica/epidemiologia , Fatores Socioeconômicos , Poluição por Fumaça de Tabaco/efeitos adversos , Índice de Gravidade de Doença , Comorbidade , Chile/epidemiologia , Prevalência , Interpretação Estatística de Dados , Inquéritos e Questionários , Fatores de Risco , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológicoRESUMO
Chronic obstructive pulmonary disease (COPD), a major cause of mortality and morbidity worldwide, is considered an archetypical disease of innate immunity, where inhaled particles and gases trigger an inflammatory response, favoring tissue proliferation in small airways and tissue destruction in lung parenchyma, in addition to the recruitment of immune cells to these compartments. Although cigarette smoking is still considered the main risk factor for developing COPD, the trend of proposing biomass smoke (BS) exposure as a principal risk factor is gaining importance, as around 3 billion people worldwide are exposed to this pollutant daily. A considerable amount of evidence has shown the potential of BS as an enhancer of lung inflammation. However, an impairment of some innate immune responses after BS exposure has also been described. Regarding the mechanisms by which biomass smoke alters the innate immune responses, three main classes of cell surface receptors-the TLRs, the scavenger receptors and the transient receptor potential channels-have shown the ability to transduce signals initiated after BS exposure. This article is an updated and comprehensive review of the immunomodulatory effects described after the interaction of BS components with these receptors.
Assuntos
Biomassa , Pulmão/imunologia , Pneumonia/imunologia , Doença Pulmonar Obstrutiva Crônica/imunologia , Poluentes Atmosféricos/efeitos adversos , Animais , Humanos , Imunidade Inata , Irritantes/efeitos adversos , Pneumonia/epidemiologia , Doença Pulmonar Obstrutiva Crônica/epidemiologia , Fatores de Risco , Fumaça/efeitos adversos , Fumar/efeitos adversosRESUMO
Approximately 3 million people in the world die every year as a consequence of COPD, which is associated with an abnormal inflammatory response of the lung to noxious particles and gases. This inflammatory pattern causes pathological changes leading to a narrowing of small airways and destruction of lung parenchyma, also known as emphysema. Classically, these changes were associated to macrophages and neutrophils, although T CD8+ lymphocytes were latter added to the equation to explain the origin of emphysematous lesions. However, in recent years, multiple evidences have arisen indicating that inflammatory response in COPD is much more complex. These findings point to a key role for mast cells, dendritic cells, T CD4+ and B cells. The aim of this article is to review such evidence and report what is known so far about those cells involved in the inflammatory response in COPD.
Assuntos
Inflamação/fisiopatologia , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , Linfócitos B/fisiologia , Linfócitos T CD4-Positivos/fisiologia , Linfócitos T CD8-Positivos/fisiologia , Células Dendríticas/fisiologia , Humanos , Macrófagos Alveolares/fisiologia , Mastócitos/fisiologia , Neutrófilos/fisiologiaRESUMO
Approximately 3 million people in the world die every year as a consequence of COPD, which is associated with an abnormal inflammatory response of the lung to noxious particles and gases. This inflammatory pattern causes pathological changes leading to a narrowing of small airways and destruction of lung parenchyma, also known as emphysema. Classically, these changes were associated to macrophages and neutrophils, although T CD8+ lymphocytes were latter added to the equation to explain the origin of emphysematous lesions. However, in recent years, multiple evidences have arisen indicating that inflammatory response in COPD is much more complex. These findings point to a key role for mast cells, dendritic cells, T CD4+ and B cells. The aim of this article is to review such evidence and report what is known so far about those cells involved in the inflammatory response in COPD.
Assuntos
Humanos , Inflamação/fisiopatologia , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , Linfócitos B/fisiologia , /fisiologia , /fisiologia , Células Dendríticas/fisiologia , Macrófagos Alveolares/fisiologia , Mastócitos/fisiologia , Neutrófilos/fisiologiaRESUMO
We report a 25 year old mole admitted to a critical care unit for fever, lung opacities and acute respiratory failure. A chest angio-CAT sean showed multiple pulmonary artery aneurysms. A deep venous thrombosis of both lower limbs was also documented. A Hughes-Stovin syndrome was postulated. An inferior vena cava filter was placed. The patient received antimicrobial therapy subsiding fever and respiratory failure. Subsequently, he was treated with intravenous and oral steroids and one dose of cyclophosphamide. The patient was discharged in good conditions fifteen days after admission.
Assuntos
Aneurisma/diagnóstico , Artéria Pulmonar , Trombose Venosa/diagnóstico , Adulto , Aneurisma/terapia , Chile , Humanos , Síndrome , Tomografia Computadorizada por Raios X , Trombose Venosa/terapiaRESUMO
We report a 25yearold mole admitted to a critical care unit for fever, lung opacities and acute respiratory failure. A chest angio-CAT sean showed multiple pulmonary artery aneurysms. A deep venous thrombosis of both lower limbs was also documented. A Hughes-Stovin syndrome was postulated. An inferior vena cava filter was placed. The patient received antimicrobial therapy subsiding fever and respiratory failure. Subsequently, he was treated with intravenous and oral steroids and one dose of cyclophosphamide. The patient was discharged in good conditions fifteen days after admission.
Assuntos
Adulto , Humanos , Aneurisma/diagnóstico , Artéria Pulmonar , Trombose Venosa/diagnóstico , Aneurisma/terapia , Chile , Síndrome , Tomografia Computadorizada por Raios X , Trombose Venosa/terapiaRESUMO
Background: Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disease, that is defined by the degree of obstruction rendered by the forced expiratory volume in the first second (FEVj). This is a good parameter to define the severity of the disease but does not account for its heterogeneity and does not provide a good comprehension of its different clinical behaviors and responses to treatment. Therefore, the classification of these patients in different clinical phenotypes has been attempted, trying to search for common clinical behaviors and responses to treatment. These phenoptypes must be validated in longitudinal studies. Some of the phenotypes detected are COPD with chronic respiratory failure and responsive to home oxygen therapy, COPD with upper lobe emphysema and responsive to volume reduction surgery, COPD with frequent exacerbation behavior, COPD resembling bronchitis and responsive to Roflumilast and possibly, COPD with systemic involvement. Historically, the phenotypes pink puffer, blue bloater, chronic bronchitis were defined. In the next years, we will know if the definitions of these phenotypes will aid in the management of patients with COPD.
Assuntos
Humanos , Doença Pulmonar Obstrutiva Crônica/genética , Bronquite/genética , Enfisema/genética , Fenótipo , Índice de Gravidade de DoençaRESUMO
Patients with chronic respiratory disease are heavy users of health care and social services resources worldwide. Although the major goals of pulmonary rehabilitation programs are to reduce levels of morbidity and to improve activity as well as participation in patients with chronic respiratory disease, their role in the management of these patients must also be validated by cost-effectiveness. Pulmonary rehabilitation's role in decreasing utilization of health care resources is an important potential benefit. Pulmonary rehabilitation is an effective intervention in patients disabled by chronic respiratory disease; however, there are relatively few studies that evaluate its effect on health care utilization. An 18-session, 6-week outpatient pulmonary rehabilitation program decreased inpatient hospital days and decreased the number of home visits when compared with standard medical management. A comprehensive cost-effectiveness analysis of the addition of this multidisciplinary pulmonary rehabilitation program to standard care for patients with chronic disabling respiratory disease concluded that the program was cost-effective and produced cost per quality-adjusted-life-years (QALY) ratios within the bounds considered to be cost-effective and therefore likely to result in financial benefits to the health care system. Patients with COPD who receive an education intervention with supervision and support based on disease-specific self management principles have decreased hospital admissions, decreased emergency department visits, and reduced number of unscheduled physician visits. This approach of care through self-management strategies is of interest because it does not require specialized resources and could be implemented within normal health care practice. In a before-after designed study, a community-based, 18-session, comprehensive pulmonary rehabilitation program was associated with an average reduction of total costs of US$344 per person per year. This wa...
Los pacientes con enfermedades respiratorias crónicas son grandes consumidores de recursos sanitarios y servicios sociales en todo el mundo. Aunque el principal objetivo de los programas de rehabilitación pulmonar es aliviar la disnea y mejorar la capacidad física, su papel en el manejo de los pacientes con afecciones respiratorias crónicas debe ser validado por estudios de costo-efectividad. La reducción del empleo de los recursos sanitarios puede ser un beneficio potencial importante de los programas de rehabilitación respiratoria multidisciplinarios. La rehabilitación pulmonar ha demostrado ser una intervención efectiva en los pacientes con discapacidad por enfermedad respiratoria crónica, sin embargo, existen relativamente pocos estudios que hayan examinado su efecto sobre la utilización de recursos sanitarios. En un programa ambulatorio de rehabilitación pulmonar de seis semanas se observó una reducción en los días de hospitalización y el número de visitas domiciliarias en comparación con el tratamiento médico estándar. El análisis de costo-efectividad de un programa de rehabilitación pulmonar multidisciplinario en pacientes con enfermedades respiratorias crónicas discapacitantes concluyó que el programa era costo-efectivo en términos de años de vida ajustados por calidad (AVAC) considerados como rentables y por lo tanto es probable que fuera económicamente beneficioso para el sistema de salud. Los pacientes con EPOC que reciben una intervención educativa con supervisión y apoyo basado en los principios de autogestión de la enfermedad disminuyen los ingresos hospitalarios, las visitas a los servicios de urgencias y el número de visitas médicas no programadas. Este enfoque de la atención, basado en estrategias de autocuidado, es de interés, ya que no requiere de recursos especializados y podría aplicarse en la práctica de salud habitual. Un programa integral de rehabilitación pulmonar basado en la comunidad se asoció a una reducción promedio de los costos...
Assuntos
Humanos , Análise Custo-Benefício , Doença Pulmonar Obstrutiva Crônica/economia , Doença Pulmonar Obstrutiva Crônica/reabilitação , Planos e Programas de Saúde/economia , Chile , Consenso , Medicina Baseada em Evidências , Custos Hospitalares , Hospitalização/economia , Avaliação de Programas e Projetos de Saúde , Unidades de Terapia Intensiva/economiaRESUMO
Chronic obstructive pulmonary disease (COPD), mainly caused by smoking, is predicted to be the third most frequent cause of death in the world by 2020. It is a multicomponent, progressive, disabling condition that ultimately ends in respiratory failure and death. There is evidence that systemic inflammation and extra pulmonary effects are also common in COPD, although the association between systemic inflammation and systemic manifestations of COPD is still not entirely clear. COPD is not only preventable but also treatable and the past decade has witnessed great progress in COPD research. New drugs have been developed and tested and a growing base of scientifc evidence now documents the efficacy of several therapies for symptoms and exacerbations. It is clear that many patients with the disease can beneft from an aggressive management, with a decrease in the frequency of hospitalizations and improvements in symptoms and quality of life. Moreover, basic and clinical scientists have now identifed cells, mechanisms, and molecules that play key roles in its pathogenesis. The advent of newer and more effective therapies will lead to a decline in the contribution of this disease to worldwide disease burden. COPD is now viewed under a new paradigm as preventable and treatable.
Assuntos
Humanos , Inflamação/tratamento farmacológico , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Inflamação/diagnóstico , Doença Pulmonar Obstrutiva Crônica/diagnósticoRESUMO
Lymphangioleiomyomatosis (LAM) is a rare interstitial lung disease, of unknown etiology, affecting almost exclusively women. Microscopically LAM consists of a diffuse proliferation of smooth muscle cells. LAM can occur without evidence of other diseases (sporadic LAM) or in conjunction with tuberous sclerosis complex (TSC). It presents with progressive breathlessness or with recurrent pneumothorax or chylothorax. We report a 33 year-old woman with a history of recurrent pneumothorax. Computed tomography (CT) scans showed numerous thin-walled cysts throughout the lungs, a characteristic finding in LAM. A pulmonary biopsy was compatible with the diagnosis and HMB-45 monoclonal antibodies were positive. Treatment with Sirolimus was started.
Assuntos
Adulto , Feminino , Humanos , Doenças Pulmonares Intersticiais/patologia , Neoplasias Pulmonares/patologia , Linfangioleiomiomatose/patologia , Anticorpos Monoclonais/análise , Neoplasias Pulmonares/complicações , Linfangioleiomiomatose/complicações , Pneumotórax/etiologia , RecidivaRESUMO
Lymphangioleiomyomatosis (LAM) is a rare interstitial lung disease, of unknown etiology, affecting almost exclusively women. Microscopically LAM consists of a diffuse proliferation of smooth muscle cells. LAM can occur without evidence of other diseases (sporadic LAM) or in conjunction with tuberous sclerosis complex (TSC). It presents with progressive breathlessness or with recurrent pneumothorax or chylothorax. We report a 33 year-old woman with a history of recurrent pneumothorax. Computed tomography (CT) scans showed numerous thin-walled cysts throughout the lungs, a characteristic finding in LAM. A pulmonary biopsy was compatible with the diagnosis and HMB-45 monoclonal antibodies were positive. Treatment with Sirolimus was started).